Table 1.

Overview of demographic and treatment characteristics.

												First post VLDRT response assessment			Post-VLDRT follow-up and further treatments
Pt	Sex	Age at VLDRT	Disease state at VLDRT	Lymphoma treatments prior to VLDRT	Duration between most recent prior biopsy and VLDRT (months)	Grade at VLDRT	Initial stage	Stage at VLDRT	Site treated with VLDRT	Max SUV on pre-VLDRT PET	LDH level prior to VLDRT	Months post VLDRT	Mode	Treatment response	Post VLDRT relapse?	Local failure	First out of VLDRT field failure	Additional therapies	Total follow-up (mos)
1	M	56	New diagnosis	none	1	3a	III	III	right submandibular	14.2	91	4.2	CT	CR	Yes		Yes (17.1 mos)***	1. Observation	21.5
2	F	84	New diagnosis	none	3	3a	II	II	multifocal head and neck	17.6	n/a	1.3	PET-CT	PR	No				11.0
3	F	52	Post observation	1. Observation x 7 years	3	3a	III	III	right parotid	10.9	190	2.2	PET-CT	CR	No				36.6
4	F	82	Post observation	"1. Observation x1.5 years 2. Excisional bx of vulvar mass"	1	3a	IV	IV	vulva and cervix	6.8	n/a	1.6	PET-CT	PR	Yes		Yes (1.5 mos)**	1. Additional course of VLDRT to in field and out of field PD 2. Considered RCHOP for subsequent DLBCL transformation but lost to follow-up	31.4
5	F	70	Post observation	"1. Excisional bx of hard palate 2. Observation x 3.5 years"	1	3a	IV	II	right neck	7.3	218	1.4	clinical	CR	No				27.4
6	F	73	Relapsed	"1. Observation x5 years 2. Rituximab monotherapy 3. R-CHOPx3 cycles with rituximab maintenance 4. R-Bendamustine x 4 cycles"	6	3a	IV	IV	right breast and axilla	6.1	211	1.9	PET-CT	CR	No				43.4
7	M	92	Relapsed	"1. 3600 to right groin 2. Rituximab monotherapy x2 3. 41.4 Gy to left groin"	106	3	II	II	right axilla, right neck, mediastinum, left neck	12.5	n/a	1.0	PET-CT	PR	Yes	Yes(6.3 mos)*	Yes (11.0 mos)	1. Full dose RT (30 Gy) to initially treated field 2. Rituximab for subsequent out of field progression	42.7
8	F	53	Relapsed	"1. CHOP x 4 with high dose cyclophosphamide 2. Rituximab monotherapy 3. VLDRT to R epitrochlear region (low grade FL)"	1	3a	Localized	II	right upper arm nodule, R axilla, R SCV	8.3	249	2.3	PET-CT	CR	No				15.7
9	F	62	Relapsed	"1. Observation x 2 years 2. Rituximab monotherapy 3. R-Bendaustine x 6 cycles 4. Rituximab monotherapy"	6	3a	III	I	pericardial node	8.0	186	2.3	PET-CT	CR	No				9.8
10	M	71	Relapsed	"1. CHOP --> R-CHOP 2. ICE 3. Rituximab monotherapy 4. Ibritumomab tiuxetan 5. Epitholone"	25	3a	I	IV	right inguinopelvic	n/a	212	1.1	PET-CT	PR	Yes	Yes (3.3 mos)	Yes (1.1 mos)	1. VLDRT to two additional fields 2. Steroids	7.3

^*Fine needle aspiration performed of VLDRT-treated site and cytology positive for malignant cells

^**First distant progression was not biopsied prior to additional RT but subsequent progression of an additional distant site which developed ~3 years after second course of VLDRT was biopsied as tranformed FL to DLBCL

^***Distant progressive site biopsied as FL grade 1-2